NEWARK, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Depomed Inc. (NASDAQ:DEPO) today announced that it has been selected to join the Collaborative for Effective Prescription Opioid Policies (CEPOP) a diverse group of over 70 stakeholders creating and advancing policies and educational initiatives aimed at reducing opioid abuse and promoting treatment options for those living with pain or confronting addiction.
“We are pleased to be joining a well-respected organization that shares our commitment to reducing prescription opioid misuse as well as highlighting the ethical and responsible prescribing and use of treatment options for those living with pain,” said Arthur Higgins, President and Chief Executive Officer of Depomed. “We look forward to engaging with this unique group of patient, family advocacy, public health, prescriber, research and supply chain organizations to develop and implement strategies to address responsible opioid use while recognizing the needs of patients in pain. At Depomed, it is clear to us that tackling these issues requires collaboration among all stakeholders, and we view this partnership with CEPOP as an important addition to our ongoing and future activities aimed at highlighting the responsible prescribing and use of opioids.”
About the Collaborative for Effective Prescription Opioid Policies (CEPOP)
Launched in January of 2015, the Collaborative for Effective Prescription Opioid Policies (CEPOP) brings together a broad array of stakeholders interested in reducing opioid medication abuse, misuse, and diversion. Specifically, CEPOP supports a comprehensive and balanced public policy agenda that reduces abuse and promotes treatment options, both for those living with pain and confronting addiction. CEPOP’s advocacy is focused on driving actions in the public sector that develop and deploy evidence-based solutions to these challenges. For more information visit https://cepoponline.org/
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.